ReviewFrontiers in public health2022
Review in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Detection ofPathogens (Basel, Switzerland) · 2026Article
- Addressing the Gaps and Challenges of Autochthonous Mucocutaneous Leishmaniasis in Spain.Tropical medicine and infectious disease · 2026Review
- Ethnic-Racial and Spatial Inequalities of American Cutaneous Leishmaniasis in Brazil: A Nationwide Analysis of Cumulative Notification and Mortality.Pathogens (Basel, Switzerland) · 2026Article
- Epidemiological, Clinical, and Socioenvironmental Characteristics of Cutaneous Leishmaniasis Cases in the Xakriabá Indigenous Population, Brazil.Acta parasitologica · 2026Observational
- Article
- Yin Yang 1: Role in Leishmaniasis.Cells · 2025Review
- One health approach toOne health (Amsterdam, Netherlands) · 2025Article
- Hemotropic mycoplasmas (hemoplasmas) in indigenous populations and their dogs living in reservation areas, Brazil.Scientific reports · 2025Article
- Article
- Selenium-Containing (Hetero)Aryl Hybrids as Potential Antileishmanial Drug Candidates: In Vitro Screening againstBiomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis, considered a neglected vector-borne disease complex of global concern, has a significant impact on indigenous communities due to daily human and animal exposure in periurban, rural, and naturally preserved areas. This mini-review aims to assess and discuss studies of leishmaniasis in these communities of the New World and Old World, particularly those in the Americas and Asia. Such indigenous communities have been mostly built in poor traditional households with no mosquito-net protection, mostly located in environmentally protected areas, favoring vectors and reservoirs. The presence of leishmaniasis cases surrounding such indigenous areas indicated a high risk of infection, which may have been historically underestimated due to a lack of surveillance, even at present. The absence of studies of indigenous populations in recognized endemic areas may reflect insufficient health services. In conclusion, the persistence of this neglectful scenario may impact tragic outcomes and potential outbreaks in indigenous peoples and surroundings populations worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.